[1] Rugge J B, Bougatsos C, Chou R.Screening and treatment of thyroid dysfunction: an evidence review for the U.S. Preventive Services Task Force[J]. Ann Intern Med, 2015, 162(1): 35-45.
[2] Canaris G J, Manowitz N R, Mayor G, et al. The Colorado thyroid disease prevalence study[J]. Arch Intern Med, 2000, 160(4): 526-534.
[3] Klein I, Ojamaa K.Thyroid hormone and the cardiovascular system[J]. N Engl J Med, 2001, 344(7): 501-509.
[4] Kenessey A, Ojamaa K.Thyroid hormone stimulates protein synthesis in the cardiomyocyte by activating the Akt-mTOR and p70S6K pathways[J]. J Biol Chem, 2006, 281(30): 20666-20672.
[5] Belke D D, Gloss B, Swanson E A, et al. Adeno-associated virus-mediated expression of thyroid hormone receptor isoforms-alpha1 and -beta1 improves contractile function in pressure overload-induced cardiac hypertrophy[J]. Endocrinology, 2007, 148(6): 2870-2877.
[6] Ripoli A, Pingitore A, Favilli B, et al. Does subclinical hypothyroidism affect cardiac pump performance? Evidence from a magnetic resonance imaging study[J]. J Am Coll Cardiol, 2005, 45(3): 439-445.
[7] Monzani F, Di Bello V, Caraccio N, et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study[J]. J Clin Endocrinol Metab, 2001, 86(3): 1110-1115.
[8] Dardano A, Ghiadoni L, Plantinga Y, et al. Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma[J]. J Clin Endocrinol Metab, 2006, 91(10): 4175-4178.
[9] Grais I M, Sowers J R.Thyroid and the heart[J]. Am J Med, 2014, 127(8): 691-698.
[10] Rodondi N, Bauer D C, Cappola A R, et al. Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study[J]. J Am Coll Cardiol, 2008, 52(14): 1152-1159.
[11] Nanchen D, Gussekloo J, Westendorp R G, et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk[J]. J Clin Endocrinol Metab, 2012, 97(3): 852-861.
[12] Lindeman R D, Romero L J, Schade D S, et al. Impact of subclinical hypothyroidism on serum total homocysteine concentrations, the prevalence of coronary heart disease (CHD), and CHD risk factors in the New Mexico Elder Health Survey[J]. Thyroid, 2003, 13(6): 595-600.
[13] Iervasi G, Molinaro S, Landi P, et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients[J]. Arch Intern Med, 2007, 167(14): 1526-1532.
[14] Rodondi N, Newman A B, Vittinghoff E, et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death[J]. Arch Intern Med, 2005, 165(21): 2460-2466.
[15] Perez A C, Jhund P S, Stott D J, et al. Thyroid-stimulating hormone and clinical outcomes: the CORONA trial (controlled rosuvastatin multinational study in heart failure)[J]. JACC Heart Fail, 2014,2(1):35-40.
[16] Hyland K A, Arnold A M, Lee J S, et al. Persistent subclinical hypothyroidism and cardiovascular risk in the elderly: the cardiovascular health study[J]. J Clin Endocrinol Metab, 2013,98(2):533-540.
[17] Waring A C, Harrison S, Samuels M H, et al. Thyroid function and mortality in older men: a prospective study[J]. J Clin Endocrinol Metab, 2012, 97(3): 862-870.
[18] Grossman A, Feldhamer I, Meyerovitch J.Treatment with levothyroxin in subclinical hypothyroidism is associated with increased mortality in the elderly[J]. Eur J Intern Med, 2018, 50: 65-68.
[19] Remaud S, Gothie J D, Morvan-Dubois G, et al. Thyroid hormone signaling and adult neurogenesis in mammals[J]. Front Endocrinol (Lausanne), 2014, 5: 62.
[20] Ge J F, Peng L, Hu C M, et al. Impaired learning and memory performance in a subclinical hypothyroidism rat model induced by hemi-thyroid electrocauterisation[J]. J Neuroendocrinol, 2012,24(6):953-961.
[21] Bajaj S, Sachan S, Misra V, et al. Cognitive function in subclinical hypothyroidism in elderly[J]. Indian J Endocrinol Metab, 2014, 18(6): 811-814.
[22] Pasqualetti G, Pagano G, Rengo G, et al. Subclinical Hypothyroidism and Cognitive Impairment: Systematic Review and Meta-Analysis[J]. J Clin Endocrinol Metab, 2015, 100(11): 4240-4248.
[23] Resta F, Triggiani V, Barile G, et al. Subclinical hypothyroidism and cognitive dysfunction in the elderly[J]. Endocr Metab Immune Disord Drug Targets, 2012,12(3):260-267.
[24] Akintola A A, Jansen S W, van Bodegom D, et al. Subclinical hypothyroidism and cognitive function in people over 60 years: a systematic review and meta-analysis[J]. Front Aging Neurosci, 2015, 7: 150.
[25] Fried L P, Tangen C M, Walston J, et al. Frailty in older adults: evidence for a phenotype[J]. J Gerontol A Biol Sci Med Sci, 2001, 56(3): M146-M156.
[26] Sergi G, Veronese N, Fontana L, et al. Pre-frailty and risk of cardiovascular disease in elderly men and women: the Pro.V.A. study[J]. J Am Coll Cardiol, 2015, 65(10): 976-983.
[27] Veronese N, Fernando-Watutantrige S, Maggi S, et al. Serum thyroid-stimulating hormone levels and frailty in the elderly: the progetto veneto anziani study[J]. Rejuvenation Res, 2017, 20(3): 165-172.
[28] Yeap B B, Alfonso H, Chubb S A, et al. Higher free thyroxine levels are associated with frailty in older men: the health in men study[J]. Clin Endocrinol (Oxf), 2012, 76(5): 741-748.
[29] Stott D J, Rodondi N, Kearney P M, et al. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism[J]. N Engl J Med, 2017,376(26):2534-2544.
[30] Den Elzen W P, Lefebre-van D F A, Virgini V, et al. International variation in GP treatment strategies for subclinical hypothyroidism in older adults: a case-based survey[J]. Br J Gen Pract, 2015, 65(631): e121-e132.